An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs IO 102 (Primary) ; IO 102 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors IO Biotech
- 27 Sep 2018 According to an IO Biotech media release, first patient has been dosed in the trial.
- 27 Aug 2018 Status changed from not yet recruiting to recruiting.
- 08 Jun 2018 Status changed from planning to not yet recruiting.